{"id":424619,"date":"2024-10-20T06:52:37","date_gmt":"2024-10-20T06:52:37","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/aami-tir22456-2022\/"},"modified":"2024-10-26T12:55:58","modified_gmt":"2024-10-26T12:55:58","slug":"aami-tir22456-2022","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/aami\/aami-tir22456-2022\/","title":{"rendered":"AAMI TIR22456 2022"},"content":{"rendered":"
Provides guidance for bioburden testing and tests of sterility for biologics and tissue-based products, where this testing is in relation to product sterilization.<\/p>\n
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
1<\/td>\n | AAMI\/ISO TIR22456:2022; Sterilization of health care products\u2014Microbiological methods\u2014Guidance on conducting bioburden determinations and tests of sterility for biologics and tissue-based products <\/td>\n<\/tr>\n | ||||||
3<\/td>\n | Title page <\/td>\n<\/tr>\n | ||||||
4<\/td>\n | Copyright information <\/td>\n<\/tr>\n | ||||||
5<\/td>\n | AAMI Technical Information Report <\/td>\n<\/tr>\n | ||||||
6<\/td>\n | Contents Page <\/td>\n<\/tr>\n | ||||||
7<\/td>\n | Committee representation <\/td>\n<\/tr>\n | ||||||
11<\/td>\n | Background of AAMI adoption of ISO\/TS 22456:2021 <\/td>\n<\/tr>\n | ||||||
12<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
13<\/td>\n | Introduction <\/td>\n<\/tr>\n | ||||||
15<\/td>\n | 1 Scope 1.1 Inclusions 1.2 Exclusions 2 Normative references <\/td>\n<\/tr>\n | ||||||
16<\/td>\n | 3 Terms and definitions <\/td>\n<\/tr>\n | ||||||
17<\/td>\n | 4 Definition and maintenance of product families 5 Selection and testing of product for bioburden and tests of sterility 5.1 General <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 5.2 Nature of product 5.3 Sample Item Portion (SIP) 5.4 Sampling conditions 5.4.1 General 5.4.2 Considerations for human tissue donor batches in sterilization 5.4.3 Use of multiple batches <\/td>\n<\/tr>\n | ||||||
19<\/td>\n | 5.4.4 Considerations for packaging 5.5 Microbiological testing 5.5.1 Bioburden test considerations for biologics\/tissues 5.5.1.1 General <\/td>\n<\/tr>\n | ||||||
20<\/td>\n | 5.5.1.2 Extraction fluid 5.5.1.3 Extraction methods 5.5.1.4 Membrane filter selection 5.5.1.5 Filtration considerations 5.5.1.6 Most Probable Number (MPN) <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | 5.5.1.7 Media for incubation 5.5.1.8 Culture conditions 5.5.1.9 Enumeration and characterization <\/td>\n<\/tr>\n | ||||||
22<\/td>\n | 5.5.1.10 Interpretation of data 5.5.2 Test of sterility considerations for biologics\/tissues 5.5.2.1 General 5.5.2.2 Performance of test of sterility 5.5.2.3 Culture conditions <\/td>\n<\/tr>\n | ||||||
23<\/td>\n | 5.5.2.4 Membrane filtration of eluate 5.5.2.5 Examination of growth medium 5.5.3 Verification of microbiological methods 5.5.3.1 Method suitability <\/td>\n<\/tr>\n | ||||||
24<\/td>\n | 5.5.3.2 Bioburden test verification (recovery efficiency test) 5.5.3.3 Method suitability for test of sterility (bacteriostasis\/fungistasis test) 5.5.4 Rapid microbiology tests <\/td>\n<\/tr>\n | ||||||
25<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" AAMI\/ISO TIR22456:2022, Sterilization of health care products\u2014Microbiological methods\u2014Guidance on conducting bioburden determinations and tests of sterility for biologics and tissue-based products<\/b><\/p>\n |